| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd115dec46c157d3739020ebd4d866b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
| filingDate |
2009-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98dcf8a3056370cd4bbb8bc4614bf18a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a33e596cf20b2fba1fddacc659aee58d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f19fcc273f9f40e42cceecbacbfb0b3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffb3c8dc81fa9a725491c86e86c885ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbac2dfb2ee37ee59ba9f2b9327d526f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e8e106cc7dc7209c7ae3ddff73d3161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49f7dc793c1037accdb4db9e3f79997e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfd9ba0d7c2dd1d203b011aabf181a23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64d63a76861b277c19eb7132da2e0424 |
| publicationDate |
2011-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20110034914-A |
| titleOfInvention |
Antibodies that specifically bind to epidermal growth factor receptor |
| abstract |
The present invention relates to an antibody that specifically binds to an epidermal growth factor receptor (EGFR). Since the antibody of the present invention exhibits excellent binding ability and neutralizing effect on the epidermal growth factor receptor, the epidermal growth factor receptor It can be used in a composition for treating cancer associated with signaling through. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015231220-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013147509-A1 |
| priorityDate |
2009-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |